Skip to content
value.today
PTC Therapeutics, Inc. logo

PTC Therapeutics, Inc.

Total raised
$115 M
5 rounds on record
Latest round
$5 M
May 2013
First round on record
Dec 2009
Today
Went public
See the company page

PTC Therapeutics, Inc. is listed today as PTC Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

5 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.

Funding rounds of PTC Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2023$36 MPrivate placement after listing$10 to $50 million

PTC Therapeutics, Inc.: Private sale, Apr 2023

Investors in this round

40 investors had bought by the notice of May 8, 2023: 40 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for PTC Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$36 M of $36 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Common Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christine E. Utter · Executive Officer · Ms. Utter is the Senior Vice President, Chief Accounting Officer and Head of People Services of the Issuer.
  • Emily E. Hill · Executive Officer · Ms. Hill is the Chief Financial Officer of the Issuer.
  • Eric E. Pauwels · Executive Officer · Mr. Pauwels is the Chief Business Officer of the Issuer.
  • Mark E. Boulding · Executive Officer · Mr. Boulding is the Executive Vice President and Chief Legal Officer of the Issuer.
  • Matthew B. Klein, M.D. · Executive Officer, Director · Dr. Klein is the Chief Executive Officer and the Director of the Development Committee of the Issuer.
  • Neil B. Almstead, Ph.D · Executive Officer · Dr. Almstead is the Chief Technical Operations Officer of the Issuer.
  • Alethia P. Young · Director
  • Allan D. Jacobson, Ph.D. · Director
  • David P. Southwell · Director
  • Emma B. Reeve · Director
  • Glenn D. Steele Jr., M.D., Ph.D. · Director
  • Jerome B. Zeldis, M.D., Ph.D. · Director
  • Mary D. Smith · Director
  • Michael B. Schmertzler · Director
  • Stepanie S. Okey · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark E. Boulding, Executive Vice President and Chief Legal Officer. Source: SEC Form D, newest notice filed May 8, 2023. Read the notice at the SEC.

equitySEC
May 2020$42 MPrivate placement after listing$10 to $50 million

PTC Therapeutics, Inc.: Private sale, May 2020

Investors in this round

38 investors had bought by the notice of Jun 12, 2020: 38 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for PTC Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$42 M of $42 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christine S. Utter · Executive Officer
  • Emily S. Hill · Executive Officer
  • Eric S. Pauwels · Executive Officer
  • Mark E. Boulding · Executive Officer
  • Matthew S. Klein · Executive Officer
  • Neil W. Almstead · Executive Officer
  • Stuart W. Peltz · Executive Officer, Director
  • Allan S. Jacobson · Director
  • David P. Southwell · Director
  • Dawn D. Svoronos · Director
  • Emma S. Reeve · Director
  • Glenn D. Steele, Jr. · Director
  • Jerome B. Zeldis · Director
  • Michael S. Schmertzler · Director
  • Stephanie S. Okey · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark E. Boulding, Executive Vice President and Chief Legal Officer. Source: SEC Form D, newest notice filed Jun 12, 2020. Read the notice at the SEC.

equitySEC
Apr 2020$141 MPrivate placement after listing$50 to $250 million

PTC Therapeutics, Inc.: Private sale, Apr 2020

Investors in this round

57 investors had bought by the notice of May 14, 2020: 57 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for PTC Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$141 M of $141 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,739,745
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christine S. Utter · Executive Officer
  • Emily S. Hill · Executive Officer
  • Eric B. Pauwels · Executive Officer
  • Mark E. Boulding · Executive Officer
  • Matthew B. Klein · Executive Officer
  • Neil W. Almstead · Executive Officer
  • Stuart W. Peltz · Executive Officer, Director
  • Allan S. Jacobson · Director
  • David P. Southwell · Director
  • Dawn D. Svoronos · Director
  • Emma S. Reeve · Director
  • Glenn D. Steele, Jr. · Director
  • Jerome B. Zeldis · Director
  • Michael S. Schmertzler · Director
  • Stephanie S. Okey · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • SVB Leerink LLC (CRD 39011) · Boston, MassachusettsSold in all US states

Signed by Mark E. Boulding, Executive Vice President and Chief Legal Officer. Source: SEC Form D, newest notice filed May 14, 2020. Read the notice at the SEC.

equitySEC
Aug 2018$150 MPrivate placement after listing$50 to $250 million

PTC Therapeutics, Inc.: Private sale, Aug 2018

Investors in this round

52 investors had bought by the notice of Sep 5, 2018: 52 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for PTC Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$150 M of $150 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christine S. Utter · Executive Officer
  • Marcio S. Souza · Executive Officer
  • Mark E. Boulding · Executive Officer
  • Neil W. Almstead · Executive Officer
  • Stuart W. Peltz · Executive Officer, Director
  • Allan S. Jacobson · Director
  • David P. Southwell · Director
  • Dawn D. Svoronos · Director
  • Glenn D. Steele, Jr. · Director
  • Jerome B. Zeldis · Director
  • Michael S. Schmertzler · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark E. Boulding, Executive Vice President and Chief Legal Officer. Source: SEC Form D, newest notice filed Sep 5, 2018. Read the notice at the SEC.

equitySEC
May 2013$5 MNo. 5$2 to $10 million

PTC Therapeutics, Inc.: Raise no. 5, May 2013

Investors in this round

1 investor had bought by the notice of May 15, 2013: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for PTC Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$315,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Claudia W. Hirawat · Executive Officer
  • Mark E. Boulding · Executive Officer
  • Stuart W. Peltz · Executive Officer, Director
  • Adam P. Koppel · Director
  • Allan S. Jacobson · Director
  • Axel P. Bolte · Director
  • David P. Southwell · Director
  • Geoffrey P. McDonough · Director
  • Jerome B. Zeldis · Director
  • Michael P. Kranda · Director
  • Michael S. Schmertzler · Director
  • Richard B. Aldrich · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Credit Suisse Securities (USA) LLC (CRD 816) · New York, New YorkSold in CO
  • Wedbush Securities Inc. (CRD 877) · Los Angeles, CaliforniaSold in CO

Signed by Mark E. Boulding, Executive Vice President and Chief Legal Officer. Source: SEC Form D, newest notice filed May 15, 2013. Read the notice at the SEC.

equitySEC
Mar 2013$60 MNo. 4$50 to $250 million

PTC Therapeutics, Inc.: Raise no. 4, Mar 2013

Investors in this round

32 investors had bought by the notice of Mar 21, 2013: 32 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for PTC Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$60 M of $60 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$3,149,970
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Claudia W. Hirawat · Executive Officer
  • Mark E. Boulding · Executive Officer
  • Stuart W. Peltz · Executive Officer, Director
  • Adam P. Koppel · Director
  • Allan S. Jacobson · Director
  • Axel P. Bolte · Director
  • David P. Southwell · Director
  • Geoffrey P. McDonough · Director
  • Jerome B. Zeldis · Director
  • Michael P. Kranda · Director
  • Michael S. Schmertzler · Director
  • Richard B. Aldrich · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Wedbush Securities Inc. (CRD 877) · Los Angeles, CaliforniaSold in CA, CT, MA, NJ, NY
  • Credit Suisse Securities (USA) LLC (CRD 816) · New York, New YorkSold in CA, CT, DC, IL, MA, MD, NJ, NY, PA

Signed by Mark E. Boulding, Executive Vice President and Chief Legal Officer. Source: SEC Form D, newest notice filed Mar 21, 2013. Read the notice at the SEC.

equitySEC
Jan 2013$2 MNo. 3$2 to $10 million

PTC Therapeutics, Inc.: Raise no. 3, Jan 2013

Investors in this round

25 investors had bought by the notice of Feb 12, 2013: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for PTC Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $16 M offered; $14 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Claudia W. Hirawat · Executive Officer
  • Mark E. Boulding · Executive Officer
  • Stuart W. Peltz · Executive Officer, Director
  • Allan S. Jacobson · Director
  • Axel P. Bolte · Director
  • David P. Southwell · Director
  • Deepa P. Pakianathan · Director
  • Geoffrey P. McDonough · Director
  • Jerome B. Zeldis · Director
  • Michael P. Kranda · Director
  • Michael S. Schmertzler · Director
  • Peter P. Svennilson · Director
  • Soren P. Carlsen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark E. Boulding, Executive Vice President and Chief Legal Officer. Source: SEC Form D, newest notice filed Feb 12, 2013. Read the notice at the SEC.

debt, optionsSEC
May 2012$23 MNo. 2$10 to $50 million

PTC Therapeutics, Inc.: Raise no. 2, May 2012

Investors in this round

27 investors had bought by the notice of Jun 13, 2012: 27 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for PTC Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$23 M of $40 M offered; $17 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Claudia W. Hirawat · Executive Officer
  • Mark E. Boulding · Executive Officer
  • Stuart W. Peltz · Executive Officer, Director
  • Allan S. Jacobson · Director
  • Axel P. Bolte · Director
  • Carl P. Goldfischer · Director
  • David P. Southwell · Director
  • Deepa P. Pakianathan · Director
  • Michael P. Kranda · Director
  • Michael S. Schmertzler · Director
  • Peter P. Svennilson · Director
  • Soren P. Carlsen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark E. Boulding, Executive Vice President and Chief Legal Officer. Source: SEC Form D, newest notice filed Jun 13, 2012. Read the notice at the SEC.

equitySEC
Dec 2009$25 MNo. 1$10 to $50 million

PTC Therapeutics, Inc.: Raise no. 1, Dec 2009

Investors in this round

21 investors had bought by the notice of Dec 22, 2009: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for PTC Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$25 M of $50 M offered; $25 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$25 million to $100 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Langdon L. Miller · Executive Officer
  • Mark E. Boulding · Executive Officer
  • Stuart W. Peltz · Executive Officer, Director
  • William E. Baird, III · Executive Officer
  • Allan S. Jacobson · Director
  • Axel P. Bolte · Director
  • Carl P. Goldfischer · Director
  • David P. Southwell · Director
  • Deepa P. Pakianathan · Director
  • Michael P. Kranda · Director
  • Michael S. Schmertzler · Director
  • Soren P. Carlsen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark E. Boulding, Senior Vice President and General Counsel. Source: SEC Form D, newest notice filed Dec 22, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company PTC Therapeutics, Inc., its revenue in fiscal 2025 came from these product and service lines: Collaboration and license revenue $998.36 million (58%), Royalty revenue $244.22 million (14%), Translarna $235.30 million (14%), Emflaza $146.36 million (8%), Sephience $111.15 million (6%).

    Annual report (SEC XBRL) · Dec 2025

  • PTC Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (May 2023).

    SEC Form D · May 2023

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · May 2023

Products and services#

No products or services of PTC Therapeutics, Inc. are on record.

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in PTC Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Cougar Investment Holdings LLCFund or asset managernot statednot statedHeld Series FIVE and FOUR preferred stock, director (Form 3, 2013)SEC Form 3
Credit Suisse AG/Companynot statednot statedHeld Series FIVE and FOUR preferred stock, 10% owner (Form 3, 2013)SEC Form 3
HBM Healthcare Investments (Cayman) Ltd.Fund or asset managernot statednot statedHeld Series FIVE and FOUR preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Vcvc III LLCOthernot statednot statedHeld Series FIVE and FOUR preferred stock, director (Form 3, 2013)SEC Form 3
VCVC Management III LLCFund or asset managernot statednot statedHeld Series FIVE and FOUR preferred stock, director (Form 3, 2013)SEC Form 3
Vulcan Capital Venture Capital I LLCVenture capitalnot statednot statedHeld Series FIVE and FOUR preferred stock, director (Form 3, 2013)SEC Form 3
Vulcan Capital Venture Capital Management I, LLCVenture capitalnot statednot statedHeld Series FIVE and FOUR preferred stock, director (Form 3, 2013)SEC Form 3
Vulcan Ventures Inc.Venture capitalnot statednot statedHeld Series FIVE and FOUR preferred stock, director (Form 3, 2013)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 32 investors.

Largest shareholders today

Institutions holding PTC Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by PTC Therapeutics, Inc.
NameRoleNamed in
Christine E. UtterMs. Utter is the Senior Vice President, Chief Accounting Officer and Head of People Services of the Issuer.May 2023
Emily E. HillMs. Hill is the Chief Financial Officer of the Issuer.May 2023
Eric E. PauwelsMr. Pauwels is the Chief Business Officer of the Issuer.May 2023
Mark E. BouldingMr. Boulding is the Executive Vice President and Chief Legal Officer of the Issuer.May 2023
Matthew B. Klein, M.D.Dr. Klein is the Chief Executive Officer and the Director of the Development Committee of the Issuer.May 2023
Neil B. Almstead, Ph.DDr. Almstead is the Chief Technical Operations Officer of the Issuer.May 2023
Christine S. UtterExecutive officerJun 2020
Emily S. HillExecutive officerJun 2020
Eric S. PauwelsExecutive officerJun 2020
Matthew S. KleinExecutive officerJun 2020
Neil W. AlmsteadExecutive officerJun 2020
Stuart W. PeltzExecutive officerJun 2020
Eric B. PauwelsExecutive officerMay 2020
Matthew B. KleinExecutive officerMay 2020
Marcio S. SouzaExecutive officerSep 2018
Claudia W. HirawatExecutive officerMay 2013
Langdon L. MillerExecutive officerDec 2009
William E. Baird, IIIExecutive officerDec 2009
Alethia P. YoungDirectorMay 2023
Allan D. Jacobson, Ph.D.DirectorMay 2023
David P. SouthwellDirectorMay 2023
Emma B. ReeveDirectorMay 2023
Glenn D. Steele Jr., M.D., Ph.D.DirectorMay 2023
Jerome B. Zeldis, M.D., Ph.D.DirectorMay 2023
Mary D. SmithDirectorMay 2023
Matthew B. Klein, M.D.Dr. Klein is the Chief Executive Officer and the Director of the Development Committee of the Issuer.May 2023
Michael B. SchmertzlerDirectorMay 2023
Stepanie S. OkeyDirectorMay 2023
Allan S. JacobsonDirectorJun 2020
Dawn D. SvoronosDirectorJun 2020
Emma S. ReeveDirectorJun 2020
Glenn D. Steele, Jr.DirectorJun 2020
Jerome B. ZeldisDirectorJun 2020
Michael S. SchmertzlerDirectorJun 2020
Stephanie S. OkeyDirectorJun 2020
Stuart W. PeltzDirectorJun 2020
Adam P. KoppelDirectorMay 2013
Axel P. BolteDirectorMay 2013
Geoffrey P. McDonoughDirectorMay 2013
Michael P. KrandaDirectorMay 2013

About

Pharmaceutical company.

Went public since 2013. Its SEC number is that of a company listed on a stock exchange.